{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:21:03Z","timestamp":1794637263886,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dermatomyositis is a chronic inflammatory disease involving the skin and muscles. It most commonly occurs in adults with preponderance in females, but pediatric occurrence is also possible. The risk of malignancy in adult patients with dermatomyositis was reported to be 4.66-fold higher compared to that in the general population. A significantly increased risk of malignancy was reported within the first 12 months following the diagnosis of dermatomyositis (standardized incidence ratio equaled 17). One of the characteristic laboratory findings associated with dermatomyositis is the presence of circulating autoantibodies which are classified into two subgroups: myositis-specific and myositis-associated autoantibodies. It was shown that specific types of antibodies might be associated with an increased risk of malignancy. Current literature data indicate that the strongest correlation with malignant diseases was reported in anti-TIF1-\u03b3-positive patients who were at a 9.37-fold higher risk of cancer. A 3.68-fold increase in the risk of cancer was also reported among patients with anti-NXP2 antibodies. Malignant diseases were reported in 14\u201357% of patients with anti-SAE antibodies. The presence of other autoantibodies may also be associated with an increased risk of malignancy. These data indicate that patients with circulating anti-TIF1-\u03b3, anti-NXP2, and anti-SAE should be very closely monitored for dermatomyositis-associated malignant comorbidities. The aim of this review is to summarize the current data regarding the link between malignancy and the presence of specific antibodies in patients with dermatomyositis.<\/jats:p>","DOI":"10.1007\/s12016-022-08922-4","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T06:02:57Z","timestamp":1644559377000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-4808","authenticated-orcid":false,"given":"Milena","family":"Marz\u0119cka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4447-282X","authenticated-orcid":false,"given":"Anna","family":"Niemczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-1023","authenticated-orcid":false,"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"8922_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5114\/dr.2021.107278","volume":"108","author":"A Reich","year":"2021","unstructured":"Reich A, Lis-\u015awi\u0119ty A, Krasowska D, Maj J, Narbutt J, Sysa-Jedrzejowska A, Wojas-Pelc A, Wo\u017aniacka A, Rudnicka L (2021) Dermatomyositis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Dermatology Review\/Przegl\u0105d Dermatologiczny 108:85\u2013104. https:\/\/doi.org\/10.5114\/dr.2021.107278","journal-title":"Dermatology Review\/Przegl\u0105d Dermatologiczny"},{"key":"8922_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1684\/ejd.2020.3761","volume":"30","author":"D Didona","year":"2020","unstructured":"Didona D, Juratli HA, Scarsella L, Eming R, Hertl M (2020) The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants. Eur J Dermatol 30:229\u2013242. https:\/\/doi.org\/10.1684\/ejd.2020.3761","journal-title":"Eur J Dermatol"},{"key":"8922_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME DeWane","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82:267\u2013281. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1309","journal-title":"J Am Acad Dermatol"},{"key":"8922_CR4","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dank\u00f3 K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O\u2019Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"8922_CR5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/bjd.15607","volume":"179","author":"C Thompson","year":"2018","unstructured":"Thompson C, Piguet V, Choy E (2018) The pathogenesis of dermatomyositis. Br J Dermatol 179:1256\u20131262. https:\/\/doi.org\/10.1111\/bjd.15607","journal-title":"Br J Dermatol"},{"key":"8922_CR6","doi-asserted-by":"publisher","unstructured":"Casal Dominguez M, Pinal-Fernandez I, Mammen A (2021) Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence. Current Treatment Options in Rheumatology. https:\/\/doi.org\/10.1007\/s40674-021-00182-1","DOI":"10.1007\/s40674-021-00182-1"},{"key":"8922_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/ard.2006.068502","volume":"66","author":"H Chinoy","year":"2007","unstructured":"Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345\u20131349. https:\/\/doi.org\/10.1136\/ard.2006.068502","journal-title":"Ann Rheum Dis"},{"key":"8922_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48\u201355. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.001","journal-title":"J Autoimmun"},{"key":"8922_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"SL Tansley","year":"2017","unstructured":"Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, Thomson W, Beresford MW, Midgley A, Muntoni F, Wedderburn LR, McHugh NJ (2017) Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 84:55\u201364. https:\/\/doi.org\/10.1016\/j.jaut.2017.06.007","journal-title":"J Autoimmun"},{"key":"8922_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft PW, Fiorentino DF (2018) Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep 20:28. https:\/\/doi.org\/10.1007\/s11926-018-0733-5","journal-title":"Curr Rheumatol Rep"},{"key":"8922_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/art.41964","author":"M Casal-Dominguez","year":"2021","unstructured":"Casal-Dominguez M, Pinal-Fernandez I, Pak K, Huang W, Selva-O\u2019Callaghan A, Albayda J, Casciola-Rosen L, Paik JJ, Tiniakou E, Mecoli CA, Lloyd TE, Danoff SK, Christopher-Stine L, Mammen AL (2021) Performance of the 2017 EULAR\/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41964","journal-title":"Arthritis Rheumatol"},{"key":"8922_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8\u201323. https:\/\/doi.org\/10.1111\/joim.12451","journal-title":"J Intern Med"},{"key":"8922_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14:290\u2013302. https:\/\/doi.org\/10.1038\/nrrheum.2018.56","journal-title":"Nat Rev Rheumatol"},{"key":"8922_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","volume":"36","author":"I Bogdanov","year":"2018","unstructured":"Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N (2018) Dermatomyositis: current concepts. Clin Dermatol 36:450\u2013458. https:\/\/doi.org\/10.1016\/j.clindermatol.2018.04.003","journal-title":"Clin Dermatol"},{"key":"8922_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.21037\/atm-20-5175","volume":"9","author":"LM Hodgkinson","year":"2021","unstructured":"Hodgkinson LM, Wu TT, Fiorentino DF (2021) Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med 9:433. https:\/\/doi.org\/10.21037\/atm-20-5175","journal-title":"Ann Transl Med"},{"key":"8922_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.rdc.2020.05.006","volume":"46","author":"S Moghadam-Kia","year":"2020","unstructured":"Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R (2020) Risk factors and cancer screening in myositis. Rheum Dis Clin North Am 46:565\u2013576. https:\/\/doi.org\/10.1016\/j.rdc.2020.05.006","journal-title":"Rheum Dis Clin North Am"},{"key":"8922_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1203475416665601","volume":"21","author":"JK Qiang","year":"2017","unstructured":"Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21:131\u2013136. https:\/\/doi.org\/10.1177\/1203475416665601","journal-title":"J Cutan Med Surg"},{"key":"8922_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1\u201319. https:\/\/doi.org\/10.1007\/s12016-015-8510-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"8922_CR19","first-page":"489","volume":"53","author":"O Stertz","year":"1916","unstructured":"Stertz O (1916) Polymyositis. Berl. Klin Wochenschr 53:489","journal-title":"Klin Wochenschr"},{"key":"8922_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","volume":"134","author":"R Buchbinder","year":"2001","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087\u20131095. https:\/\/doi.org\/10.7326\/0003-4819-134-12-200106190-00008","journal-title":"Ann Intern Med"},{"key":"8922_CR21","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1038\/s41598-021-83729-5","volume":"11","author":"J-L Hsu","year":"2021","unstructured":"Hsu J-L, Liao M-F, Chu C-C, Kuo H-C, Lyu R-K, Chang H-S, Chen C-M, Wu Y-R, Chang K-H, Weng Y-C, Chang C-W, Chiang H-I, Cheng C-K, Lee P-W, Huang C-C, Ro L-S (2021) Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep 11:4545. https:\/\/doi.org\/10.1038\/s41598-021-83729-5","journal-title":"Sci Rep"},{"key":"8922_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","volume":"16","author":"JM Olazagasti","year":"2015","unstructured":"Olazagasti JM, Baez PJ, Wetter DA, Ernste FC (2015) Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 16:89\u201398. https:\/\/doi.org\/10.1007\/s40257-015-0120-1","journal-title":"Am J Clin Dermatol"},{"key":"8922_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000009639","volume":"97","author":"H Leatham","year":"2018","unstructured":"Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D (2018) Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine (Baltimore) 97:e9639. https:\/\/doi.org\/10.1097\/md.0000000000009639","journal-title":"Medicine (Baltimore)"},{"key":"8922_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83729-5","author":"J-L Hsu","year":"2021","unstructured":"Hsu J-L, Liao M-F, Chu C-C, Kuo H-C, Lyu R-K, Chang H-S, Chen C-M, Wu Y-R, Chang K-H, Weng Y-C, Chang C-W, Chiang H-I, Cheng C-K, Lee P-W, Huang C-C, Ro L-S (2021) Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-83729-5","journal-title":"Sci Rep"},{"key":"8922_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.rpor.2014.02.005","volume":"19","author":"JW Teoh","year":"2014","unstructured":"Teoh JW, Yunus RM, Hassan F, Ghazali N, Abidin ZA (2014) Nasopharyngeal carcinoma in dermatomyositis patients: a 10-year retrospective review in Hospital Selayang, Malaysia. Rep Pract Oncol Radiother 19:332\u2013336. https:\/\/doi.org\/10.1016\/j.rpor.2014.02.005","journal-title":"Rep Pract Oncol Radiother"},{"key":"8922_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/MPH.0b013e3181bf29a2","volume":"32","author":"P Morris","year":"2010","unstructured":"Morris P, Dare J (2010) Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 32:189\u2013191. https:\/\/doi.org\/10.1097\/MPH.0b013e3181bf29a2","journal-title":"J Pediatr Hematol Oncol"},{"key":"8922_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.21037\/atm-20-5215","volume":"9","author":"U Khanna","year":"2020","unstructured":"Khanna U, Galimberti F, Li Y, Fernandez AP (2020) Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening? Ann Transl Med 9:432","journal-title":"Ann Transl Med"},{"key":"8922_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.autrev.2006.03.007","volume":"6","author":"E Szekanecz","year":"2006","unstructured":"Szekanecz E, Andr\u00e1s C, S\u00e1ndor Z, Antal-Szalm\u00e1s P, Sz\u00e1nt\u00f3 J, Tam\u00e1si L, Kiss E, Szekanecz Z (2006) Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 6:42\u201347. https:\/\/doi.org\/10.1016\/j.autrev.2006.03.007","journal-title":"Autoimmun Rev"},{"key":"8922_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/art.38928","volume":"67","author":"AA Shah","year":"2015","unstructured":"Shah AA, Casciola-Rosen L, Rosen A (2015) Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67:317\u2013326. https:\/\/doi.org\/10.1002\/art.38928","journal-title":"Arthritis Rheumatol"},{"key":"8922_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.05.002","volume":"127","author":"A Vlagea","year":"2018","unstructured":"Vlagea A, Falagan S, Guti\u00e9rrez-Guti\u00e9rrez G, Moreno-Rubio J, Merino M, Zambrana F, Casado E, Sereno M (2018) Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol 127:42\u201349. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.05.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"8922_CR31","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O\u2019Hanlon TP, Miller FW, Rider LG (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54:3682\u20133689. https:\/\/doi.org\/10.1002\/art.22164","journal-title":"Arthritis Rheum"},{"key":"8922_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","volume":"46","author":"K Kaji","year":"2007","unstructured":"Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46:25\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/kel161","journal-title":"Rheumatology (Oxford)"},{"key":"8922_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K (2012) Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513\u2013522. https:\/\/doi.org\/10.1002\/art.33403","journal-title":"Arthritis Rheum"},{"key":"8922_CR34","doi-asserted-by":"publisher","unstructured":"McAvera\u00a0RM, Crawford LJ (2020) TIF1 proteins in genome stability and cancer. Cancers (Basel) 12.\u00a0https:\/\/doi.org\/10.3390\/cancers12082094","DOI":"10.3390\/cancers12082094"},{"key":"8922_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","volume":"21","author":"GA Cobos","year":"2020","unstructured":"Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339\u2013353. https:\/\/doi.org\/10.1007\/s40257-020-00502-6","journal-title":"Am J Clin Dermatol"},{"key":"8922_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mus.25507","volume":"56","author":"M Casal-Dominguez","year":"2017","unstructured":"Casal-Dominguez M, Pinal-Fernandez I, Mego M, Accarino A, Jubany L, Azpiroz F, Selva-O\u2019callaghan A (2017) High-resolution manometry in patients with idiopathic inflammatory myopathy: elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. Muscle Nerve 56:386\u2013392. https:\/\/doi.org\/10.1002\/mus.25507","journal-title":"Muscle Nerve"},{"key":"8922_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J Am Acad Dermatol 72:449\u2013455. https:\/\/doi.org\/10.1016\/j.jaad.2014.12.009","journal-title":"J Am Acad Dermatol"},{"key":"8922_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","volume":"59","author":"J De Vooght","year":"2020","unstructured":"De Vooght J, Vulsteke JB, De Haes P, Bossuyt X, Lories R, De Langhe E (2020) Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen. Rheumatology (Oxford) 59:469\u2013477. https:\/\/doi.org\/10.1093\/rheumatology\/kez572","journal-title":"Rheumatology (Oxford)"},{"key":"8922_CR39","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum 65:2954\u20132962. https:\/\/doi.org\/10.1002\/art.38093","journal-title":"Arthritis Rheum"},{"key":"8922_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2340\/00015555-3091","volume":"99","author":"M Best","year":"2019","unstructured":"Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D (2019) Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol 99:256\u2013262. https:\/\/doi.org\/10.2340\/00015555-3091","journal-title":"Acta Derm Venereol"},{"key":"8922_CR41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/key357","volume":"58","author":"A Oldroyd","year":"2019","unstructured":"Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H (2019) The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 58:650\u2013655. https:\/\/doi.org\/10.1093\/rheumatology\/key357","journal-title":"Rheumatology (Oxford)"},{"key":"8922_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/1346-8138.15284","volume":"47","author":"N Ikeda","year":"2020","unstructured":"Ikeda N, Yamaguchi Y, Kanaoka M, Ototake Y, Akita A, Watanabe T, Aihara M (2020) Clinical significance of serum levels of anti-transcriptional intermediary factor 1-\u03b3 antibody in patients with dermatomyositis. J Dermatol 47:490\u2013496. https:\/\/doi.org\/10.1111\/1346-8138.15284","journal-title":"J Dermatol"},{"key":"8922_CR43","first-page":"990","volume":"36","author":"M Ogawa-Momohara","year":"2018","unstructured":"Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, Kakeda M, Kono M, Akiyama M (2018) Strong correlation between cancer progression and anti-transcription intermediary factor 1\u03b3 antibodies in dermatomyositis patients. Clin Exp Rheumatol 36:990\u2013995","journal-title":"Clin Exp Rheumatol"},{"key":"8922_CR44","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.3899\/jrheum.090461","volume":"36","author":"G Espada","year":"2009","unstructured":"Espada G, MALDONADO COCCO JA, FERTIG N, ODDIS CV, (2009) Clinical and serologic characterization of an argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36:2547\u20132551. https:\/\/doi.org\/10.3899\/jrheum.090461","journal-title":"J Rheumatol"},{"key":"8922_CR45","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1091\/mbc.e06-08-0747","volume":"18","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, Miyoshi J, Zinn AR, Shime H, Inoue N (2007) Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell 18:1701\u20131709. https:\/\/doi.org\/10.1091\/mbc.e06-08-0747","journal-title":"Mol Biol Cell"},{"key":"8922_CR46","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1771\u20131776. https:\/\/doi.org\/10.1002\/acr.23188","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8922_CR47","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF (2017) Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1909\u20131914. https:\/\/doi.org\/10.1002\/acr.23210","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8922_CR48","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, Fujimoto M (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:710\u2013713. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200697","journal-title":"Ann Rheum Dis"},{"key":"8922_CR49","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1002\/art.22862","volume":"56","author":"Z Betteridge","year":"2007","unstructured":"Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N (2007) Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 56:3132\u20133137. https:\/\/doi.org\/10.1002\/art.22862","journal-title":"Arthritis Rheum"},{"key":"8922_CR50","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/ard.2008.097162","volume":"68","author":"ZE Betteridge","year":"2009","unstructured":"Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, McHugh NJ (2009) Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68:1621\u20131625. https:\/\/doi.org\/10.1136\/ard.2008.097162","journal-title":"Ann Rheum Dis"},{"key":"8922_CR51","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/rheumatology\/kev247","volume":"54","author":"Y Muro","year":"2015","unstructured":"Muro Y, Sugiura K, Nara M, Sakamoto I, Suzuki N, Akiyama M (2015) High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis. Rheumatology (Oxford) 54:1745\u20131747. https:\/\/doi.org\/10.1093\/rheumatology\/kev247","journal-title":"Rheumatology (Oxford)"},{"key":"8922_CR52","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","volume":"384","author":"E Tarricone","year":"2012","unstructured":"Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A (2012) Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 384:128\u2013134. https:\/\/doi.org\/10.1016\/j.jim.2012.07.019","journal-title":"J Immunol Methods"},{"key":"8922_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","volume":"72","author":"M Fujimoto","year":"2013","unstructured":"Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, Yamaoka T, Fujikawa K, Tsukada T, Sato K, Echigo T, Hasegawa M, Takehara K (2013) Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 72:151\u2013153. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201736","journal-title":"Ann Rheum Dis"},{"key":"8922_CR54","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/acr2.11247","volume":"3","author":"J Albayda","year":"2021","unstructured":"Albayda J, Mecoli C, Casciola-Rosen L, Danoff SK, Lin CT, Hines D, Gutierrez-Alamillo L, Paik JJ, Tiniakou E, Mammen AL, Christopher-Stine L (2021) A North American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases. ACR Open Rheumatol 3:287\u2013294. https:\/\/doi.org\/10.1002\/acr2.11247","journal-title":"ACR Open Rheumatol"},{"key":"8922_CR55","doi-asserted-by":"publisher","unstructured":"Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M, Yamada H, Yamada R, Sato S, Takehara K, Kuwana M (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLOS One 8:e60442. https:\/\/doi.org\/10.1371\/journal.pone.0060442","DOI":"10.1371\/journal.pone.0060442"},{"key":"8922_CR56","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/ard.2005.040717","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, Mosca M, Vencovsky J, van Venrooij WJ, van Engelen BG (2006) Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 65:242\u2013245. https:\/\/doi.org\/10.1136\/ard.2005.040717","journal-title":"Ann Rheum Dis"},{"key":"8922_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","volume":"36","author":"A Ceribelli","year":"2017","unstructured":"Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I, Franceschini F, Cantarini L, Satoh M, Selmi C (2017) Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 36:469\u2013475. https:\/\/doi.org\/10.1007\/s10067-016-3453-0","journal-title":"Clin Rheumatol"},{"key":"8922_CR58","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/mus.24541","volume":"52","author":"V Limaye","year":"2015","unstructured":"Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, Lester S (2015) Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52:196\u2013203. https:\/\/doi.org\/10.1002\/mus.24541","journal-title":"Muscle Nerve"},{"key":"8922_CR59","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/ced.12674","volume":"40","author":"AM Molina-Ruiz","year":"2015","unstructured":"Molina-Ruiz AM, Romero F, Carrasco L, Feltes F, Haro R, Requena L (2015) Amyophatic dermatomyositis presenting as a flagellated skin eruption with positive MDA5 antibodies and thyroid cancer: a real association? Clin Exp Dermatol 40:887\u2013890. https:\/\/doi.org\/10.1111\/ced.12674","journal-title":"Clin Exp Dermatol"},{"key":"8922_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","volume":"14","author":"I Marie","year":"2012","unstructured":"Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14:275\u2013285. https:\/\/doi.org\/10.1007\/s11926-012-0249-3","journal-title":"Curr Rheumatol Rep"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08922-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:52:35Z","timestamp":1673527955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08922-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["8922"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08922-4","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"6 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}